César Magro-Checa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
César Magro-Checa has a total of 455 co-authors. Here are the top co-authors by number of shared publications:
- Javier Martin
Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain
7 shared publications - Javier Narváez
Department of Rheumatology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Faculty of Medicine and Health Sciences, Universitat de Barcelona (UB), Barcelona, Spain
7 shared publications Juan Salvatierra
Rheumatology Division, Hospital Universitario San Cecilio, Granada, Spain
7 shared publications- Juan José Alegre-Sancho
J.J. Alegre-Sancho, MD, PhD, Department of Rheumatology, Hospital Universitari Doctor Peset, Valencia
6 shared publications Mark A. van Buchem
Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
6 shared publicationsEnrique Raya
Department of Rheumatology, San Cecilio University Hospital, Granada, Spain
5 shared publications
Latest Publications
- 4 November 2026
- Published by Wiley in Arthritis Care & Research
Disease activity and patient‐perceived health: associations with the Patient Acceptable Symptom State (PASS) in a large multicenter systemic lupus erythematosus cohort
Objective: We aimed to evaluate the relationship between disease activity and the Patient Acceptable Symptom State (PASS) and to identify clinical and socio‐demographic factors associated with PASS in systemic lupus erythematosus (SLE). Methods: We analyzed data from the Spanish multicenter SLE registry (RELESSER). PASS was self‐reported. Disease activity was assessed using SLEDAI‐2K and targeted disease activity states (DORIS remission and LLDAS). Collected variables included socio‐demographic factors (age, sex, employment, educational attainment), fibromyalgia, organ damage (SDI), current therapies and the Lupus Impact Tracker (LIT). Associations with PASS were analyzed for each disease activity state measure by univariable and multivariable logistic regression. A subgroup analysis was performed in patients in DORIS remission. Results: 72% of patients (n=1249) reported being in PASS. Lower SLEDAI‐2K, DORIS remission and LLDAS were independently associated with being in PASS. Higher education level and being employed were positively associated, while female sex and fibromyalgia were negatively associated with PASS. After including LIT items in the models, DORIS remission and LLDAS remained associated, while pain, fatigue‐related limitations and anxiety showed the strongest associations. Among patients in DORIS remission, 20% were not in PASS, with female sex, fibromyalgia, pain, fatigue‐related limitations and anxiety remaining independent barriers. Conclusion: DORIS remission and LLDAS are associated with PASS, supporting their relevance as treatment targets from the patient's perspective. Pain, fatigue and anxiety hinder many patients with SLE from achieving satisfactory health beyond disease remission. One in five patients in remission is still not in PASS. PASS assessment may help capture unmet needs in SLE management. image
- 4 November 2026
- Published by Wiley in Arthritis Care & Research
Disease activity and patient‐perceived health: associations with the Patient Acceptable Symptom State (PASS) in a large multicenter systemic lupus erythematosus cohort
Objective: We aimed to evaluate the relationship between disease activity and the Patient Acceptable Symptom State (PASS) and to identify clinical and socio‐demographic factors associated with PASS in systemic lupus erythematosus (SLE). Methods: We analyzed data from the Spanish multicenter SLE registry (RELESSER). PASS was self‐reported. Disease activity was assessed using SLEDAI‐2K and targeted disease activity states (DORIS remission and LLDAS). Collected variables included socio‐demographic factors (age, sex, employment, educational attainment), fibromyalgia, organ damage (SDI), current therapies and the Lupus Impact Tracker (LIT). Associations with PASS were analyzed for each disease activity state measure by univariable and multivariable logistic regression. A subgroup analysis was performed in patients in DORIS remission. Results: 72% of patients (n=1249) reported being in PASS. Lower SLEDAI‐2K, DORIS remission and LLDAS were independently associated with being in PASS. Higher education level and being employed were positively associated, while female sex and fibromyalgia were negatively associated with PASS. After including LIT items in the models, DORIS remission and LLDAS remained associated, while pain, fatigue‐related limitations and anxiety showed the strongest associations. Among patients in DORIS remission, 20% were not in PASS, with female sex, fibromyalgia, pain, fatigue‐related limitations and anxiety remaining independent barriers. Conclusion: DORIS remission and LLDAS are associated with PASS, supporting their relevance as treatment targets from the patient's perspective. Pain, fatigue and anxiety hinder many patients with SLE from achieving satisfactory health beyond disease remission. One in five patients in remission is still not in PASS. PASS assessment may help capture unmet needs in SLE management. image
- Open Access
- 3 September 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
HRCT Phenotypes in Sarcoidosis: association with pulmonary function, inflammatory markers and organ involvement
STUDY QUESTION: Are the Delphi derived HRCT phenotypes associated with pulmonary function tests, inflammatory markers and organ involvement at presentation in newly diagnosed sarcoidosis patients? STUDY DESIGN AND METHODS: This cross-sectional study was conducted in two non-academic teaching hospitals between 2015 and 2020. Patients with a new diagnosis of sarcoidosis with baseline PFT and (HR)CT were included. CT images were systematically scored according to the Delphi HRCT phenotypes, including seven individual phenotypes (P1-P7) divided into two subgroups: “non-fibrotic” phenotypes (NFP) (P1-P4) and “likely-to-be fibrotic” phenotypes (FP) (P5-P7); and a “rest” group (not classifiable) and “null” group (no abnormalities) were identified. Differences in PFT, inflammatory markers and organ involvement were compared across phenotypes and subgroups. Logistic and linear regression was used to adjust for potential confounders. RESULTS: A total of 281 patients were included: 160 in the “NFP”, 34 in the “FP”, 8 in the “rest” and 79 in the “null” subgroup. Fibrotic phenotypes were associated with an obstructive pattern and diffusion impairment compared to NFP, with phenotypes P5 and 6 characterized by a restrictive spirometric pattern and moderate - severe diffusion impairment, and phenotype 7 characterized by an obstructive pattern and mild diffusion impairment. No consistent or clinically relevant associations were observed between CT phenotypes and inflammatory markers or organ involvement. ANSWER TO THE QUESTION: An association is for the first time demonstrated between the Delphi HRCT phenotypes and baseline PFT in newly diagnosed sarcoidosis, supporting the value of these phenotypes towards a more established CT classification.
- 3 September 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
Open AccessHRCT Phenotypes in Sarcoidosis: association with pulmonary function, inflammatory markers and organ involvement
STUDY QUESTION: Are the Delphi derived HRCT phenotypes associated with pulmonary function tests, inflammatory markers and organ involvement at presentation in newly diagnosed sarcoidosis patients? STUDY DESIGN AND METHODS: This cross-sectional study was conducted in two non-academic teaching hospitals between 2015 and 2020. Patients with a new diagnosis of sarcoidosis with baseline PFT and (HR)CT were included. CT images were systematically scored according to the Delphi HRCT phenotypes, including seven individual phenotypes (P1-P7) divided into two subgroups: “non-fibrotic” phenotypes (NFP) (P1-P4) and “likely-to-be fibrotic” phenotypes (FP) (P5-P7); and a “rest” group (not classifiable) and “null” group (no abnormalities) were identified. Differences in PFT, inflammatory markers and organ involvement were compared across phenotypes and subgroups. Logistic and linear regression was used to adjust for potential confounders. RESULTS: A total of 281 patients were included: 160 in the “NFP”, 34 in the “FP”, 8 in the “rest” and 79 in the “null” subgroup. Fibrotic phenotypes were associated with an obstructive pattern and diffusion impairment compared to NFP, with phenotypes P5 and 6 characterized by a restrictive spirometric pattern and moderate - severe diffusion impairment, and phenotype 7 characterized by an obstructive pattern and mild diffusion impairment. No consistent or clinically relevant associations were observed between CT phenotypes and inflammatory markers or organ involvement. ANSWER TO THE QUESTION: An association is for the first time demonstrated between the Delphi HRCT phenotypes and baseline PFT in newly diagnosed sarcoidosis, supporting the value of these phenotypes towards a more established CT classification.
- Open Access
- 23 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (11)
Loeffler endocarditis in hypereosinophilic syndrome, the paradox of absent peripheral eosinophilia: a case report
Background: Loeffler endocarditis is a cardiac disease characterized by infiltration of eosinophils in hypereosinophilic syndrome (HES), progressing through acute necrotic, thrombotic, and fibrotic stages. It can ultimately lead to heart failure and restrictive cardiomyopathy. Early recognition, multidisciplinary approach, and accurate treatment are crucial to prevent these complications. Case summary: A 51-year-old man presented with dyspnoea and chest discomfort. Imaging revealed a large left ventricular (LV) thrombus, a reduced LV ejection fraction (LVEF 28%), and a typical ‘double-V pattern’ of endomyocardial fibrosis. Despite characteristic imaging findings of Loeffler endocarditis, the absence of peripheral eosinophilia reduced clinical suspicion. Coronary disease was excluded by CT coronary angiography. Extended bloodwork for infectious, autoimmune, oncologic, and HES-related diseases remained negative. Myeloperoxidase tested positive; however, there were no clinical findings suggestive of eosinophilic granulomatosis with polyangiitis. Subsequently, a bone marrow biopsy confirmed eosinophilia, establishing the diagnosis of Loeffler endocarditis. The patient was treated with anticoagulation, heart failure therapy, and prednisone. At 6-month follow-up, LVEF improved slightly to 35% but the typical V-shaped LV thrombus persisted, and heart failure symptoms (NYHA III) remained. Discussion: Loeffler endocarditis is an eosinophil-mediated disease but may present without peripheral eosinophilia, particularly in longstanding cases of HES. This underscores the importance of cardiac imaging, bone marrow evaluation, and multidisciplinary collaboration in suspected cases to ensure timely diagnosis and treatment, thereby preventing disease progression.
- 23 October 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (11)
Open AccessLoeffler endocarditis in hypereosinophilic syndrome, the paradox of absent peripheral eosinophilia: a case report
Background: Loeffler endocarditis is a cardiac disease characterized by infiltration of eosinophils in hypereosinophilic syndrome (HES), progressing through acute necrotic, thrombotic, and fibrotic stages. It can ultimately lead to heart failure and restrictive cardiomyopathy. Early recognition, multidisciplinary approach, and accurate treatment are crucial to prevent these complications. Case summary: A 51-year-old man presented with dyspnoea and chest discomfort. Imaging revealed a large left ventricular (LV) thrombus, a reduced LV ejection fraction (LVEF 28%), and a typical ‘double-V pattern’ of endomyocardial fibrosis. Despite characteristic imaging findings of Loeffler endocarditis, the absence of peripheral eosinophilia reduced clinical suspicion. Coronary disease was excluded by CT coronary angiography. Extended bloodwork for infectious, autoimmune, oncologic, and HES-related diseases remained negative. Myeloperoxidase tested positive; however, there were no clinical findings suggestive of eosinophilic granulomatosis with polyangiitis. Subsequently, a bone marrow biopsy confirmed eosinophilia, establishing the diagnosis of Loeffler endocarditis. The patient was treated with anticoagulation, heart failure therapy, and prednisone. At 6-month follow-up, LVEF improved slightly to 35% but the typical V-shaped LV thrombus persisted, and heart failure symptoms (NYHA III) remained. Discussion: Loeffler endocarditis is an eosinophil-mediated disease but may present without peripheral eosinophilia, particularly in longstanding cases of HES. This underscores the importance of cardiac imaging, bone marrow evaluation, and multidisciplinary collaboration in suspected cases to ensure timely diagnosis and treatment, thereby preventing disease progression.
- 29 August 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (12) , 6440-6441
Necrotizing granulomatous mass with skin and tracheal fistulization in ANCA-associated vasculitis
- 29 August 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (12) , 6440-6441
Necrotizing granulomatous mass with skin and tracheal fistulization in ANCA-associated vasculitis
- Open Access
- 27 December 2024
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 7 (1) , tzaf017
Radiological phenotypes in pulmonary sarcoidosis: a reliability study of newly defined high-resolution computer tomography phenotypes
Objectives: An accurate morphological classification of distinct pulmonary phenotypes in sarcoidosis is lacking. Recently, a multinational Delphi study was conducted to reach a consensus on recognizable high-resolution computer tomography (HRCT) phenotypes in pulmonary sarcoidosis as a basis for a more distinctive classification. The reliability of these phenotypes has not yet been evaluated. Methods: HRCT scans of adult sarcoidosis patients from the pulmonology department of a single sarcoidosis referral center were scored by three blinded independent readers. Seven phenotypes were distinguished as described in the Delphi study. They were divided into two subgroups: “non-fibrotic” and “likely-to-be fibrotic”. Intra- and inter-reader reliability for scoring the predominant phenotype and the subgroup was assessed using weighted Kappa (Kw) statistics. Results: Forty-five patients (mean age, 47 years ± 12, 28 men) were included. For the scoring of the predominant phenotype, inter-reader reliability between all readers was substantial with an overall Fleiss’ kappa of 0.69 (CI 0.622-0.765, P < .001). We observed a substantial inter-reader reliability between readers A and B (Kw of 0.76), between readers B and C (Kw of 0.66) and between readers A and C (Kw of 0.66). For the scoring of the subgroups “non-fibrotic” vs. “likely-to-be fibrotic,” overall Fleiss’ Kappa was substantial (K = 0.78, CI 0.607-0.944, P < .001). We observed a Kw score of 0.76 between readers A and B; 0.81 between readers A and C; 0.76 between readers B and C. Intra-reader reliability was substantial between the scores of A in scoring the predominant phenotypes (Kw of 0.71) and it was almost perfect in scoring the subgroups (Kw of 0.95). Intra-reader reliability was substantial between the scores of B in scoring the predominant phenotype (Kw of 0.66) and subgroups (Kw of 0.72). Conclusions: The inter- and intra-reader reliability of the newly proposed HRCT phenotypes obtained from the Delphi study is very acceptable. Advances in knowledge: This study is the first to assess the reliability of these HRCT phenotypes and supports the use of them for classification purposes in future clinical and pathogenetic studies.
- 27 December 2024
- Published by Oxford University Press (OUP) in BJR|Open
- Vol. 7 (1) , tzaf017
Open AccessRadiological phenotypes in pulmonary sarcoidosis: a reliability study of newly defined high-resolution computer tomography phenotypes
Objectives: An accurate morphological classification of distinct pulmonary phenotypes in sarcoidosis is lacking. Recently, a multinational Delphi study was conducted to reach a consensus on recognizable high-resolution computer tomography (HRCT) phenotypes in pulmonary sarcoidosis as a basis for a more distinctive classification. The reliability of these phenotypes has not yet been evaluated. Methods: HRCT scans of adult sarcoidosis patients from the pulmonology department of a single sarcoidosis referral center were scored by three blinded independent readers. Seven phenotypes were distinguished as described in the Delphi study. They were divided into two subgroups: “non-fibrotic” and “likely-to-be fibrotic”. Intra- and inter-reader reliability for scoring the predominant phenotype and the subgroup was assessed using weighted Kappa (Kw) statistics. Results: Forty-five patients (mean age, 47 years ± 12, 28 men) were included. For the scoring of the predominant phenotype, inter-reader reliability between all readers was substantial with an overall Fleiss’ kappa of 0.69 (CI 0.622-0.765, P < .001). We observed a substantial inter-reader reliability between readers A and B (Kw of 0.76), between readers B and C (Kw of 0.66) and between readers A and C (Kw of 0.66). For the scoring of the subgroups “non-fibrotic” vs. “likely-to-be fibrotic,” overall Fleiss’ Kappa was substantial (K = 0.78, CI 0.607-0.944, P < .001). We observed a Kw score of 0.76 between readers A and B; 0.81 between readers A and C; 0.76 between readers B and C. Intra-reader reliability was substantial between the scores of A in scoring the predominant phenotypes (Kw of 0.71) and it was almost perfect in scoring the subgroups (Kw of 0.95). Intra-reader reliability was substantial between the scores of B in scoring the predominant phenotype (Kw of 0.66) and subgroups (Kw of 0.72). Conclusions: The inter- and intra-reader reliability of the newly proposed HRCT phenotypes obtained from the Delphi study is very acceptable. Advances in knowledge: This study is the first to assess the reliability of these HRCT phenotypes and supports the use of them for classification purposes in future clinical and pathogenetic studies.
- 4 April 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 226, 107608
Organ involvement in newly diagnosed sarcoidosis patients in the Netherlands: The first large European multicentre prospective study
- 4 April 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 226, 107608
Organ involvement in newly diagnosed sarcoidosis patients in the Netherlands: The first large European multicentre prospective study
- 28 November 2023
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (1) , 1-13
Differentiating between segmental arterial mediolysis and other arterial vasculopathies to establish an early diagnosis – a systematic literature review and proposal of new diagnostic criteria
Segmental arterial mediolysis (SAM) is a rare vascular disease, characterized by acute but transient vulnerability of the wall of medium-sized arteries. The most characteristic feature of SAM is its biphasic course: an injurious phase marked by acute weakness of the arterial wall leading to acute dissection and/or hemorrhage, followed by a reparative phase in which granulation tissue and fibrosis restore the injured arterial wall. Residual stenosis, aneurysms, and/or arterial wall irregularities may remain visible on future imaging studies. Differentiating between SAM and other arterial vasculopathies is difficult due to its similarities with many other vascular diseases, such as vasculitis, fibromuscular dysplasia, inherited connective tissue disorders, and isolated visceral artery dissection. In this systematic review, we provide an overview on SAM, with an emphasis on the differential diagnosis and diagnostic work-up. We propose new diagnostic criteria to help establish a prompt diagnosis of SAM, illustrated by case examples from our multidisciplinary vascular clinic.
- 28 November 2023
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (1) , 1-13
Differentiating between segmental arterial mediolysis and other arterial vasculopathies to establish an early diagnosis – a systematic literature review and proposal of new diagnostic criteria
Segmental arterial mediolysis (SAM) is a rare vascular disease, characterized by acute but transient vulnerability of the wall of medium-sized arteries. The most characteristic feature of SAM is its biphasic course: an injurious phase marked by acute weakness of the arterial wall leading to acute dissection and/or hemorrhage, followed by a reparative phase in which granulation tissue and fibrosis restore the injured arterial wall. Residual stenosis, aneurysms, and/or arterial wall irregularities may remain visible on future imaging studies. Differentiating between SAM and other arterial vasculopathies is difficult due to its similarities with many other vascular diseases, such as vasculitis, fibromuscular dysplasia, inherited connective tissue disorders, and isolated visceral artery dissection. In this systematic review, we provide an overview on SAM, with an emphasis on the differential diagnosis and diagnostic work-up. We propose new diagnostic criteria to help establish a prompt diagnosis of SAM, illustrated by case examples from our multidisciplinary vascular clinic.
- Open Access
- 25 October 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 6 (3)
MPO-ANCA-associated vasculitis in the context of autoimmune polyglandular syndrome type 3: case report and literature review
Dear Editor, A 55-year-old White man was admitted to the nephrology department with renal insufficiency, haematuria, progressive fatigue, dry cough and exertional dyspnoea. He had been suffering from general malaise and generalized arthralgias without clear signs of inflammatory arthritis for the last 6 months. His past medical history was remarkable for vitiligo, RP, hypothyroidism owing to Hashimoto’s thyroiditis with elevated thyroid peroxidase antibodies since 2011, and chronic atrophic gastritis with positive intrinsic factor and parietal cell antibodies since April 2021. He was currently treated with levothyroxine, simvastatin, carbasalate calcium, ticagrelor and metoprolol.
- 25 October 2022
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 6 (3)
Open AccessMPO-ANCA-associated vasculitis in the context of autoimmune polyglandular syndrome type 3: case report and literature review
Dear Editor, A 55-year-old White man was admitted to the nephrology department with renal insufficiency, haematuria, progressive fatigue, dry cough and exertional dyspnoea. He had been suffering from general malaise and generalized arthralgias without clear signs of inflammatory arthritis for the last 6 months. His past medical history was remarkable for vitiligo, RP, hypothyroidism owing to Hashimoto’s thyroiditis with elevated thyroid peroxidase antibodies since 2011, and chronic atrophic gastritis with positive intrinsic factor and parietal cell antibodies since April 2021. He was currently treated with levothyroxine, simvastatin, carbasalate calcium, ticagrelor and metoprolol.
- 22 October 2022
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 58, 152121
Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)
- 22 October 2022
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 58, 152121
Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)
- 20 October 2022
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 41 (4) , 961-963
18F-fluorodeoxyglucose positron emission tomography for the assessment of endo-bronchial involvement in granulomatosis with polyangiitis
Case Report; Authors: C. Magro-Checa, S.T. Laurens, D. Goudkade, G.-J. Nobel-Hoff, R.L. Mostard
- 20 October 2022
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 41 (4) , 961-963
18F-fluorodeoxyglucose positron emission tomography for the assessment of endo-bronchial involvement in granulomatosis with polyangiitis
Case Report; Authors: C. Magro-Checa, S.T. Laurens, D. Goudkade, G.-J. Nobel-Hoff, R.L. Mostard